医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Company Profile for Chugai Pharmaceutical Co., Ltd.

2015年10月02日 AM09:10
このエントリーをはてなブックマークに追加


 

Chugai Pharmaceutical (TOKYO:4519) is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2014 of Chugai totaled 461.1 billion yen and the operating income was 77.3 billion yen (IFRS Core basis).

Company:

  Chugai Pharmaceutical Co., Ltd.
 

Headquarters Address:

2-1-1 Nihonbashi-Muromachi, Chuo-ku

Tokyo 103-8324
Japan
 

Main Telephone:

81-3-3273-0881
 

Website:

http://www.chugai-pharm.co.jp/english/index.html

 

Ticker:

(TOKYO:4519)

 

Type of Organization:

Public

 

Industry:

Pharmaceutical
 

Key Executives:

Chairman & CEO: Osamu Nagayama

Deputy Chairman: Motoo Ueno

President & COO: Tatsuro Kosaka

 

Public Relations

Contact:

Koki Harada

Phone:

+81-3-3273-0881

Email:

pr@chugai-pharm.co.jp

 

Investor Relations

Contact:

Toshiya Sasai

Phone:

+81-3-3273-0554

Email:

ir@chugai-pharm.co.jp

View source version on businesswire.com: http://www.businesswire.com/news/home/20151001005038/en/

CONTACT

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc